Cargando…
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
Autores principales: | Nemet, Ital, Kliker, Limor, Lustig, Yaniv, Zuckerman, Neta, Erster, Oran, Cohen, Carmit, Kreiss, Yitshak, Alroy-Preis, Sharon, Regev-Yochay, Gili, Mendelson, Ella, Mandelboim, Michal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Massachusetts Medical Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823651/ https://www.ncbi.nlm.nih.gov/pubmed/34965337 http://dx.doi.org/10.1056/NEJMc2119358 |
Ejemplares similares
-
Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel
por: Lustig, Yaniv, et al.
Publicado: (2021) -
Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021) -
COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022
por: Kliker, Limor, et al.
Publicado: (2022) -
Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023) -
Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)